Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

The effect of intracameral injection of bevacizumab on posterior capsular opacification after congenital cataract surgery

Poster Details

First Author: M.Talebnejad IRAN

Co Author(s):    M. Rahimi   G. Roustaei           

Abstract Details



Purpose:

Posterior capsular opacification (PCO) is the most common complication of cataract surgery especially in pediatric age group. The only treatment for PCO, Nd: YAG laser capsulotomy carries vision-related complications. Pharmacological intervention during or after surgery is one of the options to prevent PCO. Bevacizumab not only has antiangiogenesis effect but also can decrease the proliferation of fibroblasts and epithelial cells. So intracameral injection of bevacizumab after cataract surgery may reduce or postpone the occurrence of PCO.

Setting:

Poostchi Eye Research Center

Methods:

Four patients with isolated bilateral congenital cataract were included in the study. Exclusion criteria were history of congenital anomaly and any other ocular pathologies. Phacoaspiration and intraocular lens implantation were done for the patients. One eye of each patient was randomly assigned to receive intracameral bevacizumab (ICB) 1.25 mg/0.05 ml and the other eye received BSS as control. Digital retroillumination image of the posterior capsule was taken 2 months and 1 year postoperatively. Image processing and calculating PCO score were done using an Objective System Capsule Analysis (OSCA).

Results:

At 2 months, a mean OSCA PCO score of 0.4346ḟ0.2191 and 0.7709ḟ0.5275 were found for the ICB and control group respectively. The values were 0.8782ḟ0.2015 and 1.2291ḟ0.2820 for the ICB and control group respectively. There were no significant difference of the mean OSCA PCO score between the two groups at 2 months and 1 year postoperatively (P=0.284 and 0.089, respectively). None of the patients underwent Nd:YAG laser capsulotomy during the follow-up period.

Conclusions:

In our pilot study which is the first one on the possible effect of bevacizumab on PCO, we found no significant difference between the PCO score of the eyes that received ICB and the controls during a 1-year follow up period. Studies with larger sample size and longer follow up period are recommended.

Financial Disclosure:

NONE

Back to previous